These results further validate GLP-1 agonists as powerful allies in combating obesity
Injection-Based Administration Subcutaneous injections: All GLP-1 RAs are administered via subcutaneous injection Prefilled pens: Most common delivery system, allows for self-administration Auto-injectors: Simplify the process for patients with dexterity issues Multi-dose pens: Require dose dialing and needle attachment Dosing frequency: Daily: Liraglutide (Saxenda, Victoza), some formulations of exenatide (Byetta) Weekly: Semaglutide (Wegovy, Ozempic), tirzepatide (Mounjaro, Zepbound), dulaglutide (Trulicity), exenatide extended-release (Bydureon) Titration schedules: Most FDA-approved GLP-1 RAs require gradual dose escalation to minimize gastrointestinal side effects
About 5-7% of clinical trial participants experienced abdominal pain
While losing significant weight, study participants also were able to keep their diabetes symptoms in check
However, if you tend towards an upset stomach, you may need to take it with food
As to be expected with any such complex regulation, the likelihood of errors that result in the impairment of function are increased
